Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P33-100UG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- GM-CSF Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: MAPARSPSPS TQPWEHVNAI QEARRLLNLS RDTAAEMNET VEVISEMFDL QEPTCLQTRL ELYKQGLRGS LTKLKGPLTM MASHYKQHCP PTPETSCATQ IITFESFKEN LKDFLLVIPF DCWEPVQE.
- Concentration
- 0.1-1.0 mg/mL
Submitted references Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL.
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.
Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.
Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines.
Bialek-Waldmann JK, Domning S, Esser R, Glienke W, Mertens M, Aleksandrova K, Arseniev L, Kumar S, Schneider A, Koenig J, Theobald SJ, Tsay HC, Cornelius ADA, Bonifacius A, Eiz-Vesper B, Figueiredo C, Schaudien D, Talbot SR, Bleich A, Spineli LM, von Kaisenberg C, Clark C, Blasczyk R, Heuser M, Ganser A, Köhl U, Farzaneh F, Stripecke R
Molecular therapy. Methods & clinical development 2021 Jun 11;21:621-641
Molecular therapy. Methods & clinical development 2021 Jun 11;21:621-641
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.
Kim SB, Ahn JH, Kim J, Jung KH
Molecular therapy. Methods & clinical development 2015;2:15031
Molecular therapy. Methods & clinical development 2015;2:15031
Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.
Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, Ku CW, Goh YY, Wahli W, Michalik L, Tan NS
The Journal of cell biology 2009 Mar 23;184(6):817-31
The Journal of cell biology 2009 Mar 23;184(6):817-31
Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines.
Chiu WK, Fann M, Weng NP
Journal of immunology (Baltimore, Md. : 1950) 2006 Dec 1;177(11):7802-10
Journal of immunology (Baltimore, Md. : 1950) 2006 Dec 1;177(11):7802-10
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect hGM-CSF by Western Blot analysis GM-CSF Polyclonal Antibody (Product # 500-P33-1MG) can be used at a concentration of 0.1- 0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant hGM-CSF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect hGM-CSF by Western Blot analysis GM-CSF Polyclonal Antibody (Product # 500-P33-1MG) can be used at a concentration of 0.1- 0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant hGM-CSF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human GM-CSF by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of GM-CSF Polyclonal Antibody (Product # 500-P33-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech GM-CSF Polyclonal Antibody, Biotin (Product # 500-P33BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human GM-CSF.
